- HER2-positive early-stage breast cancer can be treated with neoadjuvant chemotherapy to shrink tumors and increase the rate of breast conservation. - The addition of trastuzumab to neoadjuvant chemotherapy significantly increases pathological complete response (pCR) rates. Achieving pCR correlates with improved long-term outcomes. - Adding pertuzumab to trastuzumab and chemotherapy further increases pCR rates compared to chemotherapy and trastuzumab alone. Trials also suggest improved long-term outcomes with dual anti-HER2 blockade.